266 related articles for article (PubMed ID: 18269618)
1. Treatment failure with rituximab in a patient with pemphigus vulgaris.
Weger W; Aberer E
J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):387-9. PubMed ID: 18269618
[No Abstract] [Full Text] [Related]
2. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
Kong HH; Prose NS; Ware RE; Hall RP
Pediatr Dermatol; 2005; 22(5):461-4. PubMed ID: 16191003
[TBL] [Abstract][Full Text] [Related]
3. A novel therapeutic option in pemphigus vulgaris: humanized monoclonal anti-CD25 antibody.
Renkl A; Mockenhaupt M; Technau K; Herouy Y; Norgauer J
Br J Dermatol; 2004 Jun; 150(6):1220-2. PubMed ID: 15214921
[No Abstract] [Full Text] [Related]
4. Epidemiology of pemphigus in south-western Iran: a 10-year retrospective study (1991-2000).
Salmanpour R; Shahkar H; Namazi MR; Rahman-Shenas MR
Int J Dermatol; 2006 Feb; 45(2):103-5. PubMed ID: 16445496
[TBL] [Abstract][Full Text] [Related]
5. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab).
Morrison LH
J Am Acad Dermatol; 2004 Nov; 51(5):817-9. PubMed ID: 15523367
[TBL] [Abstract][Full Text] [Related]
6. Outcome of pemphigus vulgaris.
Kavusi S; Daneshpazhooh M; Farahani F; Abedini R; Lajevardi V; Chams-Davatchi C
J Eur Acad Dermatol Venereol; 2008 May; 22(5):580-4. PubMed ID: 18194237
[TBL] [Abstract][Full Text] [Related]
7. Delayed response of oral pemphigus vulgaris to rituximab treatment.
Niedermeier A; Wörl P; Barth S; Schuler G; Hertl M
Eur J Dermatol; 2006; 16(3):266-70. PubMed ID: 16709491
[TBL] [Abstract][Full Text] [Related]
8. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris.
El Tal AK; Posner MR; Spigelman Z; Ahmed AR
J Am Acad Dermatol; 2006 Sep; 55(3):449-59. PubMed ID: 16908351
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for pemphigus vulgaris.
Joly P; D'Incan M; Musette P
N Engl J Med; 2007 Feb; 356(5):521; author reply 521-2. PubMed ID: 17267915
[No Abstract] [Full Text] [Related]
10. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).
Marzano AV; Fanoni D; Venegoni L; Berti E; Caputo R
Dermatology; 2007; 214(4):310-8. PubMed ID: 17460402
[TBL] [Abstract][Full Text] [Related]
11. Schnitzler syndrome: treatment failure to rituximab but response to anakinra.
Eiling E; Möller M; Kreiselmaier I; Brasch J; Schwarz T
J Am Acad Dermatol; 2007 Aug; 57(2):361-4. PubMed ID: 17467852
[TBL] [Abstract][Full Text] [Related]
12. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris.
Faurschou A; Gniadecki R
Int J Dermatol; 2008 Mar; 47(3):292-4. PubMed ID: 18289336
[TBL] [Abstract][Full Text] [Related]
13. The prognosis of pemphigus patients will be significantly improved in the future.
Ikeda S; Komiyama E; Ogawa H
Arch Dermatol Res; 2003 Apr; 295 Suppl 1():S69-70. PubMed ID: 12677437
[No Abstract] [Full Text] [Related]
14. Successful treatment of recalcitrant pemphigus foliaceus with rituximab.
Serrão VV; Martins A; Páris FR; Lopes MP
J Eur Acad Dermatol Venereol; 2008 Jun; 22(6):768-70. PubMed ID: 18482042
[No Abstract] [Full Text] [Related]
15. Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed.
Belgi AS; Azeez M; Hoyle C; Williams RE
Clin Exp Dermatol; 2006 Jan; 31(1):143. PubMed ID: 16309516
[No Abstract] [Full Text] [Related]
16. Long-lasting remission of pemphigus vulgaris treated with rituximab.
Esposito M; Capriotti E; Giunta A; Bianchi L; Chimenti S
Acta Derm Venereol; 2006; 86(1):87-9. PubMed ID: 16586007
[No Abstract] [Full Text] [Related]
17. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature.
Cianchini G; Corona R; Frezzolini A; Ruffelli M; Didona B; Puddu P
Arch Dermatol; 2007 Aug; 143(8):1033-8. PubMed ID: 17709662
[TBL] [Abstract][Full Text] [Related]
18. A case of Sweet's syndrome and pemphigus vulgaris.
del Pozo J; Martínez W; Carro E; Arévalo MP; Rodríguez-Lozano J; Fonseca E
J Eur Acad Dermatol Venereol; 2004 Nov; 18(6):745-6. PubMed ID: 15482319
[No Abstract] [Full Text] [Related]
19. Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris.
Barrera MV; Mendiola MV; Bosch RJ; Herrera E
J Dermatolog Treat; 2007; 18(5):312-4. PubMed ID: 17852643
[TBL] [Abstract][Full Text] [Related]
20. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients.
Goh MS; McCormack C; Dinh HV; Welsh B; Foley P; Prince HM
Br J Dermatol; 2007 May; 156(5):990-6. PubMed ID: 17355229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
